VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $95,604,635 | +13.6% | 1,875,114 | +11.3% | 0.01% | +10.0% |
| Q2 2023 | $84,159,603 | +68.9% | 1,685,214 | +26.8% | 0.01% | +66.7% |
| Q1 2023 | $49,823,638 | +82931.1% | 1,329,339 | +6.2% | 0.01% | -25.0% |
| Q4 2022 | $60,006 | -99.7% | 1,251,433 | +39.9% | 0.01% | +166.7% |
| Q3 2022 | $21,474,000 | +26.6% | 894,786 | +14.8% | 0.00% | +50.0% |
| Q2 2022 | $16,966,000 | -2.7% | 779,695 | +8.0% | 0.00% | 0.0% |
| Q1 2022 | $17,435,000 | +11.8% | 721,963 | +10.1% | 0.00% | 0.0% |
| Q4 2021 | $15,599,000 | -2.5% | 655,717 | +4.0% | 0.00% | 0.0% |
| Q3 2021 | $15,997,000 | +36.9% | 630,567 | +21.5% | 0.00% | 0.0% |
| Q2 2021 | $11,682,000 | +40.5% | 518,974 | +23.3% | 0.00% | +100.0% |
| Q1 2021 | $8,312,000 | +4.1% | 420,888 | +40.0% | 0.00% | 0.0% |
| Q4 2020 | $7,986,000 | -44.7% | 300,577 | +2.8% | 0.00% | -66.7% |
| Q3 2020 | $14,439,000 | +1691.4% | 292,413 | +1045.5% | 0.00% | – |
| Q2 2020 | $806,000 | – | 25,526 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |